News

Filter By:

Article Type
  • COVID-19 provided an opportunity to show that mRNA vaccines can work. Now, drug companies are racing to apply the technology platform for influenza.

    • Elie Dolgin
    News
  • AlphaFold and RoseTTAFold have delivered a revolutionary advance for protein structure predictions, but the implications for drug discovery are more incremental. For now.

    • Asher Mullard
    News
  • Could the FDA’s supplemental approval of Novo Nordisk’s semaglutide for weight loss be a turning point for anti-obesity drugs?

    • Asher Mullard
    News
  • ‘Dangling’ accelerated approvals for immuno-oncology antibodies are raising questions about the future of this 30-year-old regulatory programme.

    • Asher Mullard
    News
  • Clinical failures of antisense candidates from two companies highlight the challenges for huntingtin-lowering approaches, but a diverse pipeline could yet provide a disease-modifying therapy.

    • Katie Kingwell
    News
  • Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year.

    • Asher Mullard
    News
  • As researchers work to understand the biology and epidemiology of post-acute COVID-19, a pioneering platform trial is now testing treatments to try to address the long-term complications of infection in previously hospitalized individuals.

    • Asher Mullard
    News
  • The FDA approved 53 novel drugs in 2020, the second highest count in over 20 years.

    • Asher Mullard
    News
  • Exosomes — small extracellular vesicles that are shed by cells — have long offered promise as drug delivery systems for small molecules, DNA, RNA and other biologic payloads. The first of these are now in the clinic.

    • Megan Cully
    News
  • The National Cancer Institute and Cancer Research UK’s US$380 million “Cancer Grand Challenges” programme highlights understudied knowledge gaps that could yet make big differences to patients.

    • Asher Mullard
    News
  • A lack of novel excipients is threatening the ability of drug developers to translate progress with small molecules and biologics into therapeutic success. The FDA could soon test a new model of excipient review to foster formulation innovation.

    • Katie Kingwell
    News
  • Fragment-based screening methodologies are proliferating, fuelled by interest in novel target space and targeted degraders.

    • Asher Mullard
    News
  • Small-molecule integrin inhibitors are catching the attention of pharmaceutical firms, with fibrosis joining gut dysfunction as a key indication for integrin-based interventions.

    • Megan Cully
    News